SCHEMBL11089588

SCHEMBL11089588

COC(=O)c1n[nH]c(N)c1C

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4C Q9H3R0 1/20 0.50
NPSR1 Q6W5P4 2/20 0.45
KDM4E B2RXH2 2/20 0.45
STAT3 P40763 1/20 0.45
HIF1A Q16665 1/20 0.45
TSHR P16473 1/20 0.44
ALDH1A1 P00352 6/20 0.38
GAA P10253 3/20 0.38
MAPT P10636 3/20 0.38
GFER P55789 2/20 0.38
MAPK1 P28482 1/20 0.38
SMN1; SMN2 Q16637 3/20 0.37
HPGD P15428 2/20 0.35
CSNK2A2 P19784 1/20 0.35
KDR P35968 1/20 0.35
CSNK2B P67870 1/20 0.35
CSNK2A1 P68400 1/20 0.35
ALPL P05186 1/20 0.35
POLB P06746 1/20 0.35
RAB9A P51151 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8317037 0.86 KDM4C (0.40) KDM4CNPSR1KDM4ESTAT3HIF1A
SCHEMBL1009945 0.82 KDM4C (0.52) KDM4CNPSR1KDM4ESTAT3HIF1A
SCHEMBL11093184 0.81 ALDH1A1 (0.50) KDM4EALDH1A1GAAMAPTSMN1; SMN2
SCHEMBL11094727 0.80 ALDH1A1 (0.41) KDM4ETSHRALDH1A1GAAMAPT
SCHEMBL16453474 0.80 KDM4C (0.53) KDM4CNPSR1KDM4ESTAT3HIF1A
SCHEMBL4714263 0.79 KDM4C (0.49) KDM4CNPSR1KDM4ESTAT3HIF1A
SCHEMBL22424292 0.79 KDM4C (0.49) KDM4CNPSR1KDM4ESTAT3HIF1A
SCHEMBL9213204 0.78 KDM4C (0.56) KDM4CNPSR1KDM4ESTAT3HIF1A
SCHEMBL12263262 0.78 HCAR2 (0.55) TSHRHCAR2KMT2A
SCHEMBL31459515 0.77 KDM4C (0.50) KDM4CNPSR1KDM4ESTAT3HIF1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2020182990-A1 FUSED RING PYRIMIDONE DERIVATIVES FOR USE IN THE TREATMENT OF HBV INFECTION OR OF HBV-INDUCED DISEASES Janssen Sciences Ireland Unlimited Company (IE) 2020-09-17 WO disclosed
CN-107735400-A Cyclic sulfamoyl arylamide derivatives and their use as medicaments for the treatment of hepatitis B 爱尔兰詹森科学公司 2018-02-23 CN disclosed
EP-0107619-A1 Dihydropyrazolo(3,4-b)pyridine derivatives and production thereof SHIONOGI & CO., LTD. (JP) 1984-05-02 EP disclosed